Loading...
Loading...
Covidien
, a leading global provider of healthcare products, today
announced that the final results of the PUFs (Pipeline for Uncoilable or
Failed Aneurysms) clinical study of its Pipeline™ embolization device have
been published in the June issue of Radiology.^1 Radiology is the official
peer-reviewed medical journal of the Radiological Society of North America.
Covidien's Pipeline is an embolization device designed to divert blood flow
away from the aneurysm in order to provide a complete and durable aneurysm
embolization while maintaining patency of the parent vessel. (Photo: Business
Wire)
The Pipeline device met the trial's primary endpoints for both effectiveness
and safety. Based on these data, the Pipeline device was approved by the U.S.
Food and Drug Administration (FDA) on April 6, 2011.
Traditional endovascular methods of treating these aneurysms have included a
reconstructive approach of filling the aneurysm sac with an embolic material
(usually detachable coils), or parent artery occlusion, where doctors attempt
to close off the affected artery. However, neither of these approaches
addresses the underlying pathology of the aneurysm.^2 ^3 ^4 ^5
Overall, 108 patients were enrolled into the study. Of the 106 evaluable
aneurysms that were treated with one or more Pipeline devices, 73.6%
completely closed (p-value <.0001) without the use of an alternative
treatment. Importantly, the occlusion rate in these patients also improved
over time, reaching 86.8% complete occlusion at one-year follow-up. These
occlusion rates are significant, especially for this challenging patient
population.
Investigators compared the Pipeline device to historical controls because no
other blood flow diverting devices are available in the U.S. Effectiveness of
stents has not been proven to FDA standards; and outcomes for surgical or
other endovascular treatments have been suboptimal.
Investigators measured safety of the device by the number of patients who
suffered an ipsilateral stroke or neurologic death in the 180 days following
the procedure. In the study, six of 107 (5.6%) patients (p-value <.0001)
suffered one of these events, significantly less than the predefined safety
threshold of 20%. The 20% threshold was based on a literature review of
adverse events rates associated with other current procedures and therapies.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in